CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, today announced that Sekar Kathiresan, M.D., chief executive officer, will be speaking at the 2019 Jefferies Gene Therapy/Editing Summit.
Dr. Kathiresan will give a corporate overview presentation on Tuesday, October 8, 2019, at 12:00 p.m. ET at the Palace Hotel in New York City. He will also participate in a panel discussion on gene editing safety and clinical/regulatory insights, to be held on Tuesday, October 8, 2019, at 1:45 p.m. ET. Verve will also be holding one-on-one meetings at the conference.
About Verve Therapeutics
Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Verve is developing therapies to safely edit the genome of adults and confer lifelong protection from coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, Verve is backed by a top-tier syndicate of investors, including GV (formerly Google Ventures), ARCH Venture Partners, F-Prime Capital, and Biomatics Capital. Verve is headquartered in Cambridge, Massachusetts. For more information, visit www.VerveTx.com.
